Search results
Results from the WOW.Com Content Network
Patiromer was generally well tolerated in studies. Side effects that occurred in more than 2% of patients included in clinical trials were mainly gastro-intestinal problems such as constipation, diarrhea, nausea, and flatulence, and also hypomagnesemia (low levels of magnesium in the blood) in 5% of patients, because patiromer binds magnesium in the gut as well.
Servier states that the use is now restricted to treatment of severe osteoporosis in postmenopausal women at high risk for fracture. [2] The European Pharmacovigilance Risk Assessment Committee (PRAC) recommended restriction in the use of strontium ranelate, based on a routine benefit-risk assessment of the medicine, which included data showing ...
CSL Vifors first treatment in this area dates back to the pioneering work of pharmacist Caspar Friedrich Hausmann in 1872 in St. Gallen. Iron-deficiency anemia , [ 22 ] inflammatory bowel disease (IBD), chronic heart failure (CHF) [ 22 ] and patient blood management (PBM) [ 22 ] are conditions treated by iron-based products of CSL Vifor.
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. [ 1 ]
The International Osteoporosis Foundation and the European Calcified Tissue Society recommend pharmacological therapy for osteoporosis in postmenopausal women and men ≥70 years, with a previous fragility fracture, or a dose equivalent of prednisone ≥7.5 mg daily for ≥3 months. For premenopausal women and men <50 years taking steroids for ...
Bisphosphonates are used to treat osteoporosis, osteitis deformans (Paget's disease of the bone), bone metastasis (with or without hypercalcemia), multiple myeloma, and other conditions involving fragile, breakable bone. In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate.
This type of treatment is taken orally. [10] It does not induce an unwanted immune response, and a single type of small molecule could be used to treat many lysosomal storage diseases. [10] Substrate reduction therapy is FDA approved and there is at least one treatment available on the market. [10]
Consequently, these drugs have been researched for the treatment of osteoporosis, [2] [3] [4] though with only limited success. [5] More recent research has suggested a number of additional applications for these drugs, such as hyperresponsiveness and inflammation in allergic asthma .